Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline

Journal of Medicinal Chemistry

Volumn 55, Issue 7, 2012, Pages 3319-3330

  Li, Kelin ^a   Frankowski, Kevin J ^a   Belon, Craig A ^b   Neuenswander, Ben ^a   Ndjomou, Jean ^c   Hanson, Alicia M ^c   Shanahan, Matthew A ^c   Schoenen, Frank J ^a   Blagg, Brian S J ^a   Aubé, Jeffrey ^a   Frick, David N ^c  

^a UNIVERSITY OF KANSAS   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DYE; HELICASE; PRIMULINE DERIVATIVE; THIOFLAVINE S DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA BINDING; DNA DENATURATION; DRUG ISOLATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NONHUMAN; REACTION OPTIMIZATION; REPLICON; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BLOOD PROTEINS; CELL LINE, TUMOR; COLORING AGENTS; HEPACIVIRUS; HUMANS; MICE; POLYMERS; PROTEIN BINDING; REPLICON; RNA HELICASES; RNA, VIRAL; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84859790281     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300021v     Document Type: Article

References (37)

1. McHutchison, J. G. Understanding hepatitis C Am. J. Manag. Care 2004, 10, S21-S29
2. Manns, M. P.; McHutchison, J. G.; Gordon, S. C.; Rustgi, V. K.; Shiffman, M.; Reindollar, R.; Goodman, Z. D.; Koury, K.; Ling, M.; Albrecht, J. K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 2001, 358, 958-965
3. Zeuzem, S.; Andreone, P.; Pol, S.; Lawitz, E.; Diago, M.; Roberts, S.; Focaccia, R.; Younossi, Z.; Foster, G. R.; Horban, A.; Ferenci, P.; Nevens, F.; Mullhaupt, B.; Pockros, P.; Terg, R.; Shouval, D.; van Hoek, B.; Weiland, O.; Van Heeswijk, R.; De Meyer, S.; Luo, D.; Boogaerts, G.; Polo, R.; Picchio, G.; Beumont, M. Telaprevir for retreatment of HCV infection N. Engl. J. Med. 2011, 364, 2417-2428
4. Bacon, B. R.; Gordon, S. C.; Lawitz, E.; Marcellin, P.; Vierling, J. M.; Zeuzem, S.; Poordad, F.; Goodman, Z. D.; Sings, H. L.; Boparai, N.; Burroughs, M.; Brass, C. A.; Albrecht, J. K.; Esteban, R. Boceprevir for previously treated chronic HCV genotype 1 infection N. Engl. J. Med. 2011, 364, 1207-1217
5. Hiraga, N.; Imamura, M.; Abe, H.; Nelson Hayes, C.; Kono, T.; Onishi, M.; Tsuge, M.; Takahashi, S.; Ochi, H.; Iwao, E.; Kamiya, N.; Yamada, I.; Tateno, C.; Yoshizato, K.; Matsui, H.; Kanai, A.; Inaba, T.; Tanaka, S.; Chayama, K. Rapid emergence of telaprevir resistant hepatitis C virus strain from wild type clone in vivo Hepatology 2011, 54, 781-788
6. Frick, D. N. The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target Curr. Issues Mol. Biol. 2007, 9, 1-20
7. Kwong, A. D.; Rao, B. G.; Jeang, K. T. Viral and cellular RNA helicases as antiviral targets Nature Rev. Drug Discovery 2005, 4, 845-853
8. Belon, C. A.; Frick, D. N. Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C Future Virol. 2009, 4, 277-293
9. Kolykhalov, A. A.; Mihalik, K.; Feinstone, S. M.; Rice, C. M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo J. Virol. 2000, 74, 2046-2051
10. Lam, A. M.; Frick, D. N. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase J. Virol. 2006, 80, 404-411
11. Mackintosh, S. G.; Lu, J. Z.; Jordan, J. B.; Harrison, M. K.; Sikora, B.; Sharma, S. D.; Cameron, C. E.; Raney, K. D.; Sakon, J. Structural and biological identification of residues on the surface of NS3 helicase required for optimal replication of the hepatitis C virus J. Biol. Chem. 2006, 281, 3528-3535
12. Paeshuyse, J.; Vliegen, I.; Coelmont, L.; Leyssen, P.; Tabarrini, O.; Herdewijn, P.; Mittendorfer, H.; Easmon, J.; Cecchetti, V.; Bartenschlager, R.; Puerstinger, G.; Neyts, J. Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors Antimicrob. Agents Chemother. 2008, 52, 3433-3437
13. Krawczyk, M.; Wasowska-Lukawska, M.; Oszczapowicz, I.; Boguszewska-Chachulska, A. M. Amidinoanthracyclines-a new group of potential anti-hepatitis C virus compounds Biol. Chem. 2009, 390, 351-360
14. Stankiewicz-Drogon, A.; Dorner, B.; Erker, T.; Boguszewska-Chachulska, A. M. Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication J. Med. Chem. 2010, 53, 3117-3126
15. Stankiewicz-Drogon, A.; Palchykovska, L. G.; Kostina, V. G.; Alexeeva, I. V.; Shved, A. D.; Boguszewska-Chachulska, A. M. New acridone-4-carboxylic acid derivatives as potential inhibitors of hepatitis C virus infection Bioorg. Med. Chem. 2008, 16, 8846-8852
16. Belon, C. A.; Frick, D. N. Monitoring helicase activity with molecular beacons BioTechniques 2008, 45 (433-40) 442
17. Boger, D. L.; Fink, B. E.; Brunette, S. R.; Tse, W. C.; Hedrick, M. P. A simple, high-resolution method for establishing DNA binding affinity and sequence selectivity J. Am. Chem. Soc. 2001, 123, 5878-5891
18. Brown, D. G.; Sanderson, M. R.; Garman, E.; Neidle, S. Crystal structure of a berenil-d(CGCAAATTTGCG) complex. An example of drug-DNA recognition based on sequence-dependent structural features J. Mol. Biol. 1992, 226, 481-490
19. Frick, D. N.; Banik, S.; Rypma, R. S. Role of divalent metal cations in ATP hydrolysis catalyzed by the hepatitis C virus NS3 helicase: magnesium provides a bridge for ATP to fuel unwinding J. Mol. Biol. 2007, 365, 1017-1032
20. Crissman, H. A.; Oka, M. S.; Steinkamp, J. A. Rapid staining methods for analysis of deoxyribonucleic acid and protein in mammalian cells J. Histochem. Cytochem. 1976, 24, 64-71
21. LeVine, H. r. Quantification of beta-sheet amyloid fibril structures with thioflavin T Methods Enzymol. 1999, 309, 274-284
22. Horobin, R. W.; Kiernan, J. A. Conn's Biological Stains: A Handbook of Dyes, Stains and Fluorochromes for Use in Biology and Medicine, 10th ed.; BIOS Scientific Publishers: Oxford, UK, 2002; pp 357-358.
23. Sharp, A.; Crabb, S. J.; Johnson, P. W.; Hague, A.; Cutress, R.; Townsend, P. A.; Ganesan, A.; Packham, G. Thioflavin S (NSC71948) interferes with Bcl-2-associated athanogene (BAG-1)-mediated protein-protein interactions J. Pharmacol. Exp. Ther. 2009, 331, 680-689
24. Karlsson, H. J.; Lincoln, P.; Westman, G. Synthesis and DNA binding studies of a new asymmetric cyanine dye binding in the minor groove of [poly(dA-dT)]2 Bioorg. Med. Chem. 2003, 11, 1035-1040
25. Bengtsson, M.; Karlsson, H. J.; Westman, G.; Kubista, M. A new minor groove binding asymmetric cyanine reporter dye for real-time PCR Nucleic Acids Res. 2003, 31, e45
26. Lohmann, V.; Korner, F.; Koch, J.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 1999, 285, 110-113
27. Krieger, N.; Lohmann, V.; Bartenschlager, R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations J. Virol. 2001, 75, 4614-4624
28. Blight, K. J.; McKeating, J. A.; Rice, C. M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication J. Virol. 2002, 76, 13001-13014
29. Huang, Y.; Chen, X. C.; Konduri, M.; Fomina, N.; Lu, J.; Jin, L.; Kolykhalov, A.; Tan, S. L. Mechanistic link between the anti-HCV effect of interferon gamma and control of viral replication by a Ras-MAPK signaling cascade Hepatology 2006, 43, 81-90
30. Gemma, S.; Butini, S.; Campiani, G.; Brindisi, M.; Zanoli, S.; Romano, M. P.; Tripaldi, P.; Savini, L.; Fiorini, I.; Borrelli, G.; Novellino, E.; Maga, G. Discovery of potent nucleotide-mimicking competitive inhibitors of hepatitis C virus NS3 helicase Bioorg. Med. Chem. Lett. 2011, 21, 2776-2779
31. Najda-Bernatowicz, A.; Krawczyk, M.; Stankiewicz-Drogon, A.; Bretner, M.; Boguszewska-Chachulska, A. M. Studies on the anti-hepatitis C virus activity of newly synthesized tropolone derivatives: identification of NS3 helicase inhibitors that specifically inhibit subgenomic HCV replication Bioorg. Med. Chem. 2010, 18, 5129-5136
32. Chen, C. S.; Chiou, C. T.; Chen, G. S.; Chen, S. C.; Hu, C. Y.; Chi, W. K.; Chu, Y. D.; Hwang, L. H.; Chen, P. J.; Chen, D. S.; Liaw, S. H.; Chern, J. W. Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase J. Med. Chem. 2009, 52, 2716-2723
33. Lam, A. M.; Keeney, D.; Eckert, P. Q.; Frick, D. N. Hepatitis C virus NS3 ATPases/helicases from different genotypes exhibit variations in enzymatic properties J. Virol. 2003, 77, 3950-3961
34. Heck, J. A.; Lam, A. M.; Narayanan, N.; Frick, D. N. Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes Antimicrob. Agents Chemother. 2008, 52, 1901-1911
35. Frick, D. N.; Ginzburg, O.; Lam, A. M. A method to simultaneously monitor hepatitis C virus NS3 helicase and protease activities Methods Mol. Biol. 2010, 587, 223-233
36. Belon, C. A.; Frick, D. N. Fuel specificity of the hepatitis C virus NS3 helicase J. Mol. Biol. 2009, 388, 851-864
37. Lanzetta, P. A.; Alvarez, L. J.; Reinach, P. S.; Candia, O. A. An improved assay for nanomole amounts of inorganic phosphate Anal. Biochem. 1979, 100, 95-97